Endoscopic Pulsed Electric Field Treatment of the Duodenum for Early Type 2 Diabetes
Tests pulsENDO, an endoscopic duodenum procedure, in adults recently diagnosed with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Duodenal pulsENDO as an Early Treatment for Type 2 DM
Key facts
- Where
- Shatin, Hong KongSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07376486, who can take part
Where in Hong Kong
- Chinese University of Hong KongShatin, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT07376486
- Record updated
- 15 September 2026
- Original description
This study is designed to evaluate the efficacy and safety of endoscopic duodenal re-cellularization therapy using pulsed electric field in individuals with in patients with a recent diagnosis of type 2 diabetes mellitus (T2DM).Read full original descriptionShow less
Duodenal Recellularization Via Electroporation Therapy as an Early Treatment for Type 2 Diabetes Mellitus (DREAM-1 Study)
This study is designed to evaluate the efficacy and safety of endoscopic duodenal re-cellularization therapy using pulsed electric field in individuals with in patients with a recent diagnosis of type 2 diabetes mellitus (T2DM).
Inclusion: Duration of T2DM </= 2 years; HbA1c </= 7.5%; On 0-1 oral diabetes medications.
Exclusion: Previous treatment with pulsENDO or similar procedure; Previous GI surgery that could preclude the ability to perform pulsENDO, or acute gastric and duodenal pathology that increased the risk of pulsENDO; Currently taking prescription antithrombotic therapy (e.g., anticoagulant or antiplatelet agent) within 10 days prior to study and/or there is a need or expected need to use during the study period; Currently taking medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics); Patients who have used non-steroidal analgesics and anti-inflammatory drugs (NSAID) and corticosteroids in the past 1 month; Type I DM, DM secondary to specific disease or having any history of ketoacidosis; Any inflammatory disease of the gastrointestinal tract such as Crohn's disease; Abnormal pathologies or conditions of the gastrointestinal tract, including duodenal polyps, ulcers or upper gastrointestinal bleeding conditions within 3 months of study; Underlying uncontrolled endocrine problem that leads to obesity, including and not limited to hypothyroidism, Cushing syndrome and eating disorder; Malignancy; Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma); Mental or psychiatric disorder; Drug or alcohol addiction; Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/microliter or known coagulopathy; Fasting C-peptide level <0.5ug/L; Patients with contra-indications to endoscopy; Pregnant or breast feeding; ASA grade IV \& V; Other cases deemed by the examining physician as unsuitable for safe treatment; Refusal to participate.